$SLDB News
Last published 1d ago
- 1d agoSLDBSolid Biosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireCHARLESTOWN, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conference:
- 6d agoSLDBSolid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireCHARLESTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular
- 1w agoSLDBSolid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 - - Solid has scheduled a Type C meeting with the FDA
- 2w agoSLDBSolid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s AtaxiaGlobeNewswire- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia - - SGT-212 is a first-in-class dual route FA
- 3w agoSLDBSolid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026GlobeNewswireCHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular
- 2mo agoSLDBSolid Biosciences to Participate at Upcoming Investor ConferencesGlobeNewswireCHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular
- 3mo agoSLDBSolid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 - - Solid expects to meet with the FDA in late Q4 2026
- 5mo agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 5mo agoSLDBSolid Biosciences to Participate at Upcoming Investor ConferencesGlobeNewswireCHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 6mo agoSLDBSolid Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agency and Orphan drug
- 6mo agoSLDBSolid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular DystrophyGlobeNewswire- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global regulatory
- 6mo agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 6mo agoSLDBSolid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell TherapyGlobeNewswire- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.
- 6mo agoSLDBSolid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular DystrophyGlobeNewswire- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - CHARLESTOWN, Mass.,
- 7mo agoSLDBSolid Biosciences to Participate at Upcoming Investor ConferencesGlobeNewswireCHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 8mo agoSLDBSolid Biosciences Announces Oversubscribed $240 Million Private PlacementGlobeNewswireCHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that
- 8mo agoSLDBSolid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceGlobeNewswireCHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced
- 8mo agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 9mo agoSLDBSolid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular DystrophyGlobeNewswire- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for
- 9mo agoSLDBSolid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireCHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 10mo agoSLDBSolid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101GlobeNewswire- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - -
- 10mo agoSLDBSolid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's AtaxiaGlobeNewswire- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026,
- 10mo agoSLDBSolid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's AtaxiaGlobeNewswireCHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 10mo agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 11mo agoSLDBSolid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human ServicesGlobeNewswireCHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 11mo agoSLDBSolid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) ForumGlobeNewswireCHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 11mo agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 11mo agoSLDBSolid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's AtaxiaGlobeNewswire– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich's ataxia – – FALCON Phase 1b clinical trial
- 11mo agoSLDBSolid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101GlobeNewswire- Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) --
- 1y agoSLDBSolid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular DystrophyGlobeNewswire- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - - New Innovative Licensing and Access Pathway (ILAP) designation provides unique,
- 1y agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 1y agoSLDBSolid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory DiscussionsGlobeNewswire- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with the FDA to discuss
- 1y agoSLDBSolid Biosciences to Participate at Upcoming Investor ConferencesGlobeNewswireCHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 1y agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 1y agoSLDBSolid Biosciences to Present at Upcoming Scientific MeetingsGlobeNewswireCHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from
- 1y agoSLDBSolid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific MeetingGlobeNewswireCHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.
- 1y agoSLDBSolid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101GlobeNewswire- Non-exclusive license for Solid's proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio's gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an
- 1y agoSLDBSolid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoSLDBSolid Biosciences to Participate at Upcoming Investor ConferencesGlobeNewswireCHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 1y agoSLDBSolid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 - - FA (SGT-212): Phase 1b trial
- 1y agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 1y agoSLDBSolid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)GlobeNewswire- SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying
- 1y agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 1y agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 1y agoSLDBSolid Biosciences to Participate at the Jefferies Global Healthcare ConferenceGlobeNewswireCHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 1y agoSLDBSolid Biosciences Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire- Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant
- 1y agoSLDBSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today
- 1y agoSLDBSolid Biosciences to Participate at The Citizens Life Sciences ConferenceGlobeNewswireCHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac
- 1y agoSLDBSolid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual MeetingGlobeNewswireCHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from
- 1y agoSLDBSolid Biosciences to Participate at Upcoming Investor ConferencesGlobeNewswireCHARLESTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac